Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?

Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1.

[1]  G. Remuzzi,et al.  B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. , 2016, Journal of the American Society of Nephrology : JASN.

[2]  L. Rostaing,et al.  Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation , 2015, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  P. Mundel,et al.  Developing therapeutic ‘arrows’ with the precision of William Tell: the time has come for targeted therapies in kidney disease , 2015, Current opinion in nephrology and hypertension.

[4]  Richard J. Johnson,et al.  Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis , 2015, Pediatric Nephrology.

[5]  P. Walker,et al.  B7-1 immunostaining in proteinuric kidney disease. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  C. Wasserfall,et al.  Minimal change disease: a dysregulation of the podocyte CD80–CTLA-4 axis? , 2014, Pediatric Nephrology.

[7]  M. Rastaldi,et al.  Role of podocyte B7-1 in diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[8]  J. Reiser,et al.  Abatacept in B7-1-positive proteinuric kidney disease. , 2014, The New England journal of medicine.

[9]  V. Torres,et al.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. , 2014, Journal of the American Society of Nephrology : JASN.

[10]  P. Mundel,et al.  Abatacept in B7-1-positive proteinuric kidney disease. , 2014, The New England journal of medicine.

[11]  R. Glassock Therapy of relapsing minimal-change disease in adults: a new approach? , 2013, Kidney international.

[12]  V. D’Agati,et al.  Focal segmental glomerulosclerosis. , 2011, The New England journal of medicine.

[13]  D. Harris,et al.  Adriamycin nephropathy: A model of focal segmental glomerulosclerosis , 2011, Nephrology.

[14]  W. Oyen,et al.  Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[15]  M. Segal,et al.  Urinary CD80 excretion increases in idiopathic minimal-change disease. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  J. Nagy,et al.  [Focal segmental glomerulosclerosis]. , 2008, Orvosi hetilap.

[17]  S. Almo,et al.  B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. , 2006, Immunology letters.

[18]  R. Kalluri,et al.  Induction of B7-1 in podocytes is associated with nephrotic syndrome. , 2004, The Journal of clinical investigation.

[19]  M. Endoh,et al.  Costimulatory molecules CD80 and CD86 in human crescentic glomerulonephritis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  D. Sahali,et al.  [Recent approaches to the pathogenesis of minimal change nephrotic syndrome]. , 2003, Nephrologie.

[21]  Bali Pulendran,et al.  Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo1 , 2001, The Journal of Immunology.

[22]  A. Fogo Minimal change disease and focal segmental glomerulosclerosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  J. Alcazar,et al.  Clinical characteristics of ischaemic renal disease. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  J. Tobin,et al.  Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. , 1997, Journal of the American Society of Nephrology : JASN.

[25]  J. Gribben,et al.  In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. , 1997, Blood.